Hybrid work is here to stay — here’s how leaders should adjust

Executives across the life sciences share their tips for navigating the new norm of remote work.

By Taren Grom • Nov. 18, 2022

4 pioneering social media campaigns in pharma this year

The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

By Karissa Waddick • Nov. 17, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Is AI just hype or a real revolution in pharma? It’s complicated

Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

By Michael Gibney • Nov. 17, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

By Kelly Bilodeau • Nov. 14, 2022

Why the IRA will drive up the country’s drug bill — not lower it

On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

By John LaMattina • Nov. 14, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

Novo Nordisk’s quantum bet on ‘world changing’ computing

Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

By Taren Grom • Nov. 10, 2022

3 ways pharma can weather a recession

If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

By Michael Gibney • Nov. 10, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

After numerous setbacks, here’s where the Huntington’s pipeline stands

A look at emerging treatments and where there’s hope for patients.

By Kelly Bilodeau • Nov. 7, 2022

What pharma could gain — or lose — from the midterms

With control of the House and Senate both up for grabs, and potentially leaning Republican, here’s what the midterm elections mean for pharma. 

By Karissa Waddick • Nov. 7, 2022

flipMD by GoodRx decreases physician burnout through medical matchmaking

Using flipMD, organizations can find, vet, connect with and source practicing board-certified physicians from all specialties for contract, project-based or full-time assignments.

Nov. 7, 2022

The other ‘D’ in DE&I

How companies can work to include people with disabilities into broader equity aims.

By Taren Grom • Nov. 4, 2022

‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.

By Michael Gibney • Nov. 3, 2022

Woman of the Week: City of Hope’s Gulden Mesara

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

By Taren Grom • Nov. 2, 2022

Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

By Alexandra Pecci • Nov. 1, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Tips for tackling trial recruitment and retention woes in oncology

How new tools are helping companies find and keep cancer patients in clinical studies.

By Kelly Bilodeau • Oct. 31, 2022

Vaccine chief’s exit spurs new slate of GSK executive changes

How the pharma giant is consolidating power as it looks to become a dominant force in the vaccine market. 

By Karissa Waddick • Oct. 31, 2022

Pharma execs on creating a better workplace culture

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

By Taren Grom • Oct. 28, 2022

Riches, rags, riches: Is Biogen the Cinderella of biotechs?

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

By Michael Gibney • Oct. 27, 2022

Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann

The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.

By Taren Grom • Oct. 26, 2022

Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

By Karissa Waddick • Oct. 26, 2022